Two‐stage penalized regression screening to detect biomarker–treatment interactions in randomized clinical trials

Jixiong Wang, Ashish Patel, James M.S. Wason and Paul J. Newcombe

Biometrics, 2022, vol. 78, issue 1, 141-150

Abstract: High‐dimensional biomarkers such as genomics are increasingly being measured in randomized clinical trials. Consequently, there is a growing interest in developing methods that improve the power to detect biomarker–treatment interactions. We adapt recently proposed two‐stage interaction detecting procedures in the setting of randomized clinical trials. We also propose a new stage 1 multivariate screening strategy using ridge regression to account for correlations among biomarkers. For this multivariate screening, we prove the asymptotic between‐stage independence, required for familywise error rate control, under biomarker–treatment independence. Simulation results show that in various scenarios, the ridge regression screening procedure can provide substantially greater power than the traditional one‐biomarker‐at‐a‐time screening procedure in highly correlated data. We also exemplify our approach in two real clinical trial data applications.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://doi.org/10.1111/biom.13424

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bla:biomet:v:78:y:2022:i:1:p:141-150

Ordering information: This journal article can be ordered from
http://www.blackwell ... bs.asp?ref=0006-341X

Access Statistics for this article

More articles in Biometrics from The International Biometric Society
Bibliographic data for series maintained by Wiley Content Delivery ().